Thomas Meier to become new COO of Bachem Group
News | Bachem AG
DECEMBER 19, 2018
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG has announced that Thomas Meier will succeed Dr. Alex Fässler as Chief Operations Officer (COO) of Bachem Group from January 1, 2019.
Dr. Fässler will retire at the end of April 2019 but will continue to serve Bachem in an advisory capacity.
Head of production
Thomas Meier was born in 1968 in Schaffhausen. After an apprenticeship as chemical laboratory technician at the ETH in Zurich and obtaining a degree in chemistry from the ZHAW School of Engineering, Mr. Meier joined Bachem AG in 1993 as Team Head, Active Pharmaceutical Ingredients.
From 2001 to 2004, Thomas Meier headed up peptide manufacturing at Peninsula Laboratories, Inc. in San Carlos, California. On his return to Switzerland, he took charge of solid-phase peptide manufacturing for Bachem AG in Bubendorf.
Former COO Europe
Mr. Meier assumed overall responsibility for production at the Bubendorf site in 2013, and was appointed COO Europe in August 2017, with responsibility for all production sites in Switzerland, Germany, and the UK.
In parallel with his work, Thomas Meier obtained a degree as Industrial Engineer STA (Swiss Technical Association) and completed the Advanced Management Programme at INSEAD Business School, Fontainebleau/Paris.
Dr. Kuno Sommer, Chairman of Bachem’s Board of Directors, wished Thomas Meier every success in his new role and remarked: “We are delighted to have found a very experienced and competent internal successor for Alex Fässler in the person of Thomas Meier. Thanks to his many years of service with Bachem, he will ensure continuity in this key function, is already well acquainted with the demanding tasks involved, and has an excellent network both inside the Group and beyond.”
“We wish to thank Alex Fässler for the substantial contribution he has made to shaping Bachem’s success story over 20 years and in various positions. He is handing over to his successor an organization with global capabilities and state-of-the-art production facilities. We wish him all the best for the future,” concluded Dr. Sommer.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.
Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107